

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#21
NB
03/26/02

Application of: Gentz et al.

Art Unit: 1646

Application Serial No.: 09/006,352

Examiner: O'Hara, E.

Filed: January 13, 1998

Attorney Docket No.: PF454

Title: Tumor Necrosis Factor 6 α and 6 β

THIRD SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.56

Commissioner for Patents and Trademarks
Washington, D.C. 20231

RECEIVED
PTO CENTER 1600/2900
02 MAR 19 PM 3:12

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of an claim of the subject application, Attorneys/Agents for Applicants hereby direct the Examiner's attention to references BC-BH listed on the attached revised form PTO/SB/08. A copy of each of the references is enclosed.

Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of this application are related to SEQ ID NOS: 29783 and 63238 in copending U.S. Patent Application Serial No. 09/912,293. A legible copy of that portion of U.S. Patent Application Serial No. 09/912,293 which caused it to be listed on the attached revised form PTO/SB/08 is submitted herewith as reference BC.

03/26/2002 HBROWN 00000002 083425 09006352

01 FC:126

180.00 CH


Identification of the listed reference is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such reference is available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to appropriate action to establish patentability over the listed document should it be applied as a reference against the claims of the subject application.

Applicants respectfully request that the Examiner review the listed reference and that the reference be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(c), since this information disclosure statement is being filed before the mailing date of a final action under §1.113, a notice of allowance under §1.311, or an action that otherwise closes prosecution in the application, a fee of \$180.00 is believed due in connection herewith. If Applicants are in error, please charge any additional required fees to Human Genome Sciences, Inc., Deposit Account No. 08-3425.

Respectfully submitted,

Date: March 19, 2002



Kenley K. Hoover (Reg. No. 40,302)
Agent for Applicants

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (301) 610-5771

KKH/MS/vsr